First-In-Human, Proof-of-Mechanism Phase 1 Study of the Oral MRGPRX2 Antagonist SEP-631 Utilizing Short Wave Infrared Imaging to Assess Response to an Icatibant Skin Challenge

Jody R. Tversky; Christina C. Chang; Donald W. MacGlashan; Monica Gangal; Lily Mak; Jasleen Sodhi; David Lau; Heather M. Byers; Annemarie Lekkerkerker; Elizabeth Alexander; Jae Kim; Sarbjit S. Saini

doi:10.1016/j.jaci.2025.12.964

First-In-Human, Proof-of-Mechanism Phase 1 Study of the Oral MRGPRX2 Antagonist SEP-631 Utilizing Short Wave Infrared Imaging to Assess Response to an Icatibant Skin Challenge

Journal of Allergy and Clinical Immunology 2026

View at publisher

Authors: Jody R. Tversky, Christina C. Chang, Donald W. MacGlashan, Monica Gangal, Lily Mak, Jasleen Sodhi, David Lau, Heather M. Byers, Annemarie Lekkerkerker, Elizabeth Alexander, Jae Kim, Sarbjit S. Saini

DOI: 10.1016/j.jaci.2025.12.964

Cited by: 0

Fields of Study & Subjects

Mast cells and histamine Food Allergy and Anaphylaxis Research Dermatology and Skin Diseases

Publication details

Journal / source: Journal of Allergy and Clinical Immunology
Volume: 157
Issue: 2
Pages: AB431–AB431
Publication date: 1 February 2026
Language: EN